RecruitingPhase 2Phase 3NCT05789056

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

A Multicenter, Open Label Study of QRX003 Lotion in Subjects With Netherton Syndrome

Sponsor

Quoin Pharmaceuticals

Enrollment

20 participants

Start Date

Mar 14, 2023

Study Type

INTERVENTIONAL

Conditions

Netherton Syndrome

Summary

To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome

Eligibility

Min Age: 14 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called QRX003, 4% Lotion for people with netherton syndrome. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 14 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.